Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07136467

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-Segmental Vitiligo (NSV) Alopecia Alopecia Areata Bacterial Infections Bacterial Infections and Mycoses Hair Diseases Hidradenitis Hidradenitis Suppurativa Hypotrichosis Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Britanico de Buenos Aires /ID# 278940, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
  • Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Exclusion criteria

  • Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
  • Unable or unwilling to comply with study requirements and PRO collection

Treatment and study plan

Primary outcomes

  1. Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only

    Time frame: Up to Day 1

    AASIS- is a scale assessing the severity of AA-related symptoms on daily functioning. Each item scored on a 0-10 Likert scale, where 0 = not present and 10 = as bad as you can imagine Higher total score = greater impact

  2. Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only

    Time frame: Up to Day 1

    SALT is a Tool developed to quantify AA-related hair loss Total score of 0-100, with 0 = no hair loss, and 100 = complete hair loss

  3. Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only

    Time frame: Up to Day 1

    F-VASI is a quantitative scoring tool used to evaluate the extent and severity of facial vitiligo calculated by multiplying the degree of skin depigmentation of the face

  4. Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only

    Time frame: Up to Day 1

    VitiQoL is a 16-item instrument assessing impact of vitiligo on QoL. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"

  5. Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only

    Time frame: Up to Day 1

    CDLQI is a10-question index measuring health-related quality of life (HRQoL) over the last 7 days for patients suffering from a skin disease. The DLQI is used in participants aged 16 and over and the CDLQI has been validated from the ages of 4 to 16 years. Each item scored on a 4-point Likert scale, where 0 = not at all/not relevant/question unanswered and 3 = very much. Maximum total score = 30 (highest impact on QoL).

  6. Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only

    Time frame: Up to Day 1

    The IHS4 score is calculated as follows: number of nodules (multiplied by 1) + number of abscesses (multiplied by 2) + number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.

Study contacts

Contact information is provided by the study sponsor or research team.

Beth Rycroft

CONTACT

[email protected]

844-663-3742

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)

Acronym: MEASUREAAVitHS

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 22, 2025
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.